ADHD - Treatment Options and Consequences of Neglect
DOI:
https://doi.org/10.12775/QS.2024.17.53428Keywords
ADHD, hyperactivity, methylphenidate, atomoxetine, viloxazine, stimulantsAbstract
Purpose of Research: Attention Deficit Hyperactivity Disorder (ADHD) is one of the most frequently diagnosed neurodevelopmental disorders. It is estimated to occur in approximately 5-10% of children and adolescents. This paper aims to highlight the challenges faced by individuals suffering from ADHD, present risk factors, summarize current treatment methods, and outline the consequences of neglecting treatment.
Methods: Databases such as PubMed, Medline, and ResearchGate were used.
Basic Results: The goal of ADHD treatment is to reduce the severity of symptoms and improve the social, academic, and emotional functioning of children and adolescents. The choice of treatment and the selection of a specific medication depend on the patient's age and coexisting disorders.
Conclusions: ADHD often coexists with other mental disorders, complicating diagnosis and treatment. Lack of or ineffective treatment has consequences such as learning difficulties, disruptions in peer and family relationships. It correlates with higher rates of traffic accidents, accidental injuries, earlier onset, and higher rates of substance abuse.
References
Lebeña A, Faresjö Å, Jones MP, Bengtsson F, Faresjö T, Ludvigsson J. Early environmental predictors for attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and their co-occurrence: The prospective ABIS-Study. Sci Rep. 2024 Jun 26;14(1):14759. doi: 10.1038/s41598-024-65067-4. PMID: 38926504; PMCID: PMC11208583.
Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among U.S. Children and Adolescents, 2016. J Clin Child Adolesc Psychol. 2018 Mar-Apr;47(2):199-212. doi: 10.1080/15374416.2017.1417860. Epub 2018 Jan 24. PMID: 29363986; PMCID: PMC5834391.
Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):250-63. doi: 10.1016/j.jaac.2012.12.014. Epub 2013 Feb 8. PMID: 23452682; PMCID: PMC3589108.
Fleming M, Fitton CA, Steiner MFC, McLay JS, Clark D, King A, Mackay DF, Pell JP. Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr. 2017 Jul 3;171(7):e170691. doi: 10.1001/jamapediatrics.2017.0691. Epub 2017 Jul 3. PMID: 28459927; PMCID: PMC6583483.
Lin PI, Wu WT, Azasu EK, Wong TY. Pathway from attention-deficit/hyperactivity disorder to suicide/self-harm. Psychiatry Res. 2024 Jul;337:115936. doi: 10.1016/j.psychres.2024.115936. Epub 2024 Apr 29. PMID: 38705042.
Pastor P, Reuben C, Duran C, Hawkins L. Association between diagnosed ADHD and selected characteristics among children aged 4-17 years: United States, 2011-2013. NCHS Data Brief. 2015 May;(201):201. PMID: 25974000.
Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, Evans SW, Flinn SK, Froehlich T, Frost J, Holbrook JR, Lehmann CU, Lessin HR, Okechukwu K, Pierce KL, Winner JD, Zurhellen W; SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019 Oct;144(4):e20192528. doi: 10.1542/peds.2019-2528. Erratum in: Pediatrics. 2020 Mar;145(3):e20193997. doi: 10.1542/peds.2019-3997. PMID: 31570648; PMCID: PMC7067282.
Holbrook JR, Cuffe SP, Cai B, Visser SN, Forthofer MS, Bottai M, Ortaglia A, McKeown RE. Persistence of Parent-Reported ADHD Symptoms From Childhood Through Adolescence in a Community Sample. J Atten Disord. 2016 Jan;20(1):11-20. doi: 10.1177/1087054714539997. Epub 2014 Jul 3. PMID: 24994874; PMCID: PMC4474771.
Uchida M, DiSalvo M, Walsh D, Biederman J. The Heritability of ADHD in Children of ADHD Parents: A Post-hoc Analysis of Longitudinal Data. J Atten Disord. 2023 Feb;27(3):250-257. doi: 10.1177/10870547221136251. Epub 2022 Nov 16. PMID: 36384349; PMCID: PMC9969349.
Shen F, Zhou H. Advances in the etiology and neuroimaging of children with attention deficit hyperactivity disorder. Front Pediatr. 2024 Jun 10;12:1400468. doi: 10.3389/fped.2024.1400468. PMID: 38915870; PMCID: PMC11194347.
Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, Farajzadeh L, Voloudakis G, Bendl J, Zeng B, Zhang W, Grove J, Als TD, Duan J, Satterstrom FK, Bybjerg-Grauholm J, Bækved-Hansen M, Gudmundsson OO, Magnusson SH, Baldursson G, Davidsdottir K, Haraldsdottir GS, Agerbo E, Hoffman GE, Dalsgaard S, Martin J, Ribasés M, Boomsma DI, Soler Artigas M, Roth Mota N, Howrigan D, Medland SE, Zayats T, Rajagopal VM; ADHD Working Group of the Psychiatric Genomics Consortium; iPSYCH-Broad Consortium; Nordentoft M, Mors O, Hougaard DM, Mortensen PB, Daly MJ, Faraone SV, Stefansson H, Roussos P, Franke B, Werge T, Neale BM, Stefansson K, Børglum AD. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat Genet. 2023 Feb;55(2):198-208. doi: 10.1038/s41588-022-01285-8. Epub 2023 Jan 26. Erratum in: Nat Genet. 2023 Apr;55(4):730. doi: 10.1038/s41588-023-01350-w. PMID: 36702997; PMCID: PMC10914347.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MMJ, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BSG, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, van den Brink W, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818. doi: 10.1016/j.neubiorev.2021.01.022. Epub 2021 Feb 4. PMID: 33549739; PMCID: PMC8328933.
Groom MJ, Cortese S. Current Pharmacological Treatments for ADHD. Curr Top Behav Neurosci. 2022;57:19-50. doi: 10.1007/7854_2022_330. PMID: 35507282.
Barbaresi WJ, Campbell L, Diekroger EA, Froehlich TE, Liu YH, O'Malley E, Pelham WE Jr, Power TJ, Zinner SH, Chan E. The Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder: Process of Care Algorithms. J Dev Behav Pediatr. 2020 Feb/Mar;41 Suppl 2S:S58-S74. doi: 10.1097/DBP.0000000000000781. PMID: 31996578.
Stutzman DL, Dopheide JA. Practice Pearls for Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder in Youth. J Pediatr Pharmacol Ther. 2024 Jun;29(3):215-231. doi: 10.5863/1551-6776-29.3.215. Epub 2024 Jun 10. PMID: 38863854; PMCID: PMC11163912.
Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015 Aug;2(8):702-709. doi: 10.1016/S2215-0366(15)00271-0. Epub 2015 Jul 22. PMID: 26249301.
Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011 Aug;99(2):211-6. doi: 10.1016/j.pbb.2011.01.020. Epub 2011 Feb 2. PMID: 21295057; PMCID: PMC3129015.
Radonjić NV, Bellato A, Khoury NM, Cortese S, Faraone SV. Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. CNS Drugs. 2023 May;37(5):381-397. doi: 10.1007/s40263-023-01005-8. Epub 2023 May 11. PMID: 37166701.
Newcorn JH, Krone B, Dittmann RW. Nonstimulant Treatments for ADHD. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):417-435. doi: 10.1016/j.chc.2022.03.005. Epub 2022 May 11. PMID: 35697393.
Cutler AJ, Mattingly GW, Jain R, O'Neal W. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectr. 2022 Apr;27(2):199-207. doi: 10.1017/S1092852920001984. Epub 2020 Oct 30. PMID: 33121553.
Baweja R, Faraone SV, Childress AC, Weiss MD, Loo SK, Wilens TE et al. From Consensus Statement to Pills to Pixels: New Innovations in Attention-Deficit/Hyperactivity Disorder Care. Journal of Child and Adolescent Psychopharmacology. 2024. doi: 10.1089/cap.2024.0022
Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Cutler AJ, Jones NJ, Findling RL, Schwabe S. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clin Ther. 2020 Aug;42(8):1452-1466. doi: 10.1016/j.clinthera.2020.05.021. Epub 2020 Jul 25. PMID: 32723670.
Jain R, Katic A. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder. Prim Care Companion CNS Disord. 2016 Aug 18;18(4). doi: 10.4088/PCC.16r01979. PMID: 27828696.
Heal DJ, Gosden J, Smith SL. New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development. Curr Top Behav Neurosci. 2022;57:79-126. doi: 10.1007/7854_2022_332. PMID: 35507283.
Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther. 2009 Jan;31(1):142-76. doi: 10.1016/j.clinthera.2009.01.015. PMID: 19243715.
O'Connor L, Carbone S, Gobbo A, Gamble H, Faraone SV. Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):799-812. doi: 10.1080/17512433.2023.2249414. Epub 2023 Aug 22. Erratum in: Expert Rev Clin Pharmacol. 2024 Apr;17(4):413. doi: 10.1080/17512433.2023.2295153. PMID: 37587841.
Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE. Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies. Neuropsychiatr Dis Treat. 2020 Jun 8;16:1411-1426. doi: 10.2147/NDT.S242084. PMID: 32606695; PMCID: PMC7292254.
Surman CBH Walsh DM, Horick N, DiSalvo M, Vater CH, Kaufman D. Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study. J Clin Psychiatry. 2023 Oct 9 and PM 84(6):23m14934. doi: 10.4088/JCP.23m14934
Surman C Vaudreuil C, Boland H, Rhodewalt L, DiSalvo M, Biederman J. L-Threonic Acid Magnesium Salt Supplementation in ADHD: An Open-Label Pilot Study. J Diet Suppl. 2021 and 32162987 18(2):119-131. doi: 10.1080/19390211.2020.1731044
Allahyari P, Abbas Torki S, Aminnezhad Kavkani B, Mahmoudi Z, Mousavi Hoseini MS, Moradi M, Alami F, Keshavarz Mohammadian M, Bahoo Sele Bani S, Abbasi Mobarakeh K, Shafaei H, Khoshdooz S, Hajipour A, Doaei S, Gholamalizadeh M. A systematic review of the beneficial effects of prebiotics, probiotics, and synbiotics on ADHD. Neuropsychopharmacol Rep. 2024 Jun;44(2):300-307. doi: 10.1002/npr2.12437. Epub 2024 Apr 16. PMID: 38623929; PMCID: PMC11144606.
Sibley MH, Shelton CR, Garcia I, Monroy JM, Hill DM, Johansson M, Link K, Greenwood L, Torres Antunez G, Reyes Francisco JC. Are There Long-Term Effects of Behavior Therapy for Adolescent ADHD? A Qualitative Study. Child Psychiatry Hum Dev. 2023 Aug;54(4):985-996. doi: 10.1007/s10578-021-01294-4. Epub 2022 Jan 18. PMID: 35039978.
Halmøy A, Ring AE, Gjestad R, Møller M, Ubostad B, Lien T, Munkhaugen EK, Fredriksen M. Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial. BMC Psychiatry. 2022 Nov 28;22(1):738. doi: 10.1186/s12888-022-04356-6. PMID: 36443712; PMCID: PMC9706966.
Mittal S, Bax A, Blum NJ, Shults J, Barbaresi W, Cacia J, Deavenport-Saman A, Friedman S, LaRosa A, Loe IM, Tulio S, Vanderbilt D, Harstad E; DBPNet Steering Committee; DBPNet Steering Committee. Receipt of Behavioral Therapy in Preschool-Age Children with ADHD and Coexisting Conditions: A DBPNet Study. J Dev Behav Pediatr. 2023 Dec 1;44(9):e651-e656. doi: 10.1097/DBP.0000000000001216. Epub 2023 Sep 26. PMID: 37751569.
Storebø OJ, Elmose Andersen M, Skoog M, Joost Hansen S, Simonsen E, Pedersen N, Tendal B, Callesen HE, Faltinsen E, Gluud C. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2019 Jun 21;6(6):CD008223. doi: 10.1002/14651858.CD008223.pub3. PMID: 31222721; PMCID: PMC6587063.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Klara Wojciechowska, Monika Turek, Aleksandra Jaroń, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Adrian Borkowski, Mateusz Sawicki
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 254
Number of citations: 0
